Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA
Status:
Unknown status
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Surface thrombogenicity of standard double lumen catheters (stDLC) and surface modified
film-coated domain structured double lumen catheters (fcDLC) consisting of a novel reactive
polyurethane copolymer coating showed that in vitro measured surface thrombogenicity was
reduced in the modified catheter compared with standard catheter. The clinical investigation
revealed that both number of days before catheter removal according to clinical requirements
and number of treatments per catheter were significantly higher with the modified catheter as
compared with the standard catheter.
Recombinant tissue plasminogen activator (rt-PA) has been used primarily to treat catheter
thrombosis. The relatively high cost of rt-PA and its theoretical potential to cause
bleeding, as well as the morbidity and mortality associated with catheter malfunction and
infection, justify the need for more definitive evidence of the efficacy of rt-PA as a
locking solution.
No study aims to evaluate the impact of rt-PA locking in long-term Hemodialysis (HD) uncuffed
catheters survival.